Report

TABLE OF CONTENTS
1 INTRODUCTION 45
1.1 OBJECTIVES OF THE STUDY 45
1.2 MARKET DEFINITION 45
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET 45
1.4 LIMITATIONS 47
1.5 MARKETS COVERED 48
2 MARKET SEGMENTATION 50
2.1 MARKETS COVERED 50
2.2 GEOGRAPHICAL SCOPE 51
2.3 YEARS CONSIDERED FOR THE STUDY 52
2.4 CURRENCY AND PRICING 52
2.5 DBMR TRIPOD DATA VALIDATION MODEL 53
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
2.7 MULTIVARIATE MODELLING 57
2.8 DBMR MARKET POSITION GRID 58
2.9 VENDOR SHARE ANALYSIS 59
2.10 MARKET END-USER COVERAGE GRID 60
2.11 SECONDARY SOURCES 61
2.12 ASSUMPTIONS 61
3 EXECUTIVE SUMMARY 62
4 PREMIUM INSIGHTS 68
4.1 PORTERS FIVE FORCES ANALYSIS 69
4.2 BRAND OUTLOOK 70
4.2.1 BRAND COMPARATIVE ANALYSIS OF KEY MIDDLE EAST AND AFRICA PLAYERS 70
4.2.1.1 BRAND COMPARATIVE NARRATIVE (ANALYTICAL OVERVIEW) 71
4.2.2 PRODUCT VS BRAND OVERVIEW - MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET 72
4.2.2.1 PRODUCT OVERVIEW - ENDOSCOPIC HEMOSTASIS DEVICES 72
4.2.2.2 BRAND OVERVIEW - INFLUENCE ON MIDDLE EAST AND AFRICA CLINICAL ADOPTION 72
4.3 CONSUMER BUYING BEHAVIOUR 73
4.3.1 CLINICAL EFFECTIVENESS AND PATIENT OUTCOMES 73
4.3.2 COST AND VALUE CONSIDERATIONS 73
4.3.3 COMPATIBILITY AND INTEGRATION 73
4.3.4 TRAINING REQUIREMENTS AND EASE OF USE 73
4.3.5 REIMBURSEMENT AND HEALTHCARE POLICY ALIGNMENT 73
4.3.6 PROCUREMENT PROCESSES AND BULK AGREEMENTS 74
4.3.7 INFLUENCE OF CLINICAL STAKEHOLDERS 74
4.3.8 TRENDS IN BUYER BEHAVIOUR 74
4.3.9 CONCLUSION 74
4.4 PATENT ANALYSIS 75
4.4.1 PATENT QUALITY AND STRENGTH - MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET 75
4.4.2 COUNTRY PATENT LANDSCAPE 75
4.4.3 IP STRATEGY AND MANAGEMENT 77
4.4.4 LICENSING AND COLLABORATION 77
4.5 RAW MATERIAL COVERAGE 79
4.5.1 METALLIC COMPONENTS AND ALLOY SYSTEMS 79
4.5.2 POLYMERIC AND SYNTHETIC MATERIALS 79
4.5.3 NATURAL AND BIOCOMPATIBLE MATERIALS 79
4.5.4 ELECTRICAL AND THERMAL MATERIAL SYSTEMS 80
4.5.5 EXPENDABLE ACCESSORIES AND SINGLE-USE MATERIALS 80
4.6 TECHNOLOGICAL ADVANCEMENTS IN MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET 81
4.6.1 ENHANCED MECHANICAL HEMOSTASIS TOOLS 81
4.6.2 ADVANCED THERMAL COAGULATION AND ENERGY-BASED SYSTEMS 81
4.6.3 NOVEL TOPICAL HEMOSTATIC AGENTS 81
4.6.4 INTEGRATION WITH ADJUNCTIVE DIAGNOSTIC TECHNOLOGIES 81
4.6.5 DEVELOPMENT OF MULTIFUNCTIONAL AND COMBINATION DEVICES 81
4.6.6 IMPROVED USER ERGONOMICS AND DEVICE DEPLOYMENT SYSTEMS 82
4.6.7 CONCLUSION 82
4.7 VALUE CHAIN ANALYSIS 83
4.7.1 OVERVIEW 83
4.7.2 RAW MATERIALS & COMPONENTS 83
4.7.3 DEVICE DESIGN, R&D & MANUFACTURING 84
4.7.4 PROCESSING, FINISHING & STERILIZATION 84
4.7.5 PACKAGING & LABELING 84
4.7.6 LOGISTICS, DISTRIBUTION & COMMERCIALIZATION 84
4.7.7 CONCLUSION 84
4.8 VENDOR SELECTION CRITERIA 85
4.8.1 CLINICAL PERFORMANCE 85
4.8.2 REGULATORY COMPLIANCE AND APPROVALS 85
4.8.3 COST AND TOTAL VALUE PROPOSITION 85
4.8.4 SUPPLY CHAIN ROBUSTNESS AND LOGISTICS 85
4.8.5 SUPPORT, TRAINING AND CLINICAL EDUCATION 85
4.8.6 QUALITY SYSTEMS AND REPROCESSING GUIDANCE 85
4.8.7 REPUTATION, PEER ACCEPTANCE AND POST-MARKET PERFORMANCE 85
4.8.8 INNOVATION AND FUTURE-READINESS 86
4.9 COMPANY EVALUATION QUADRANT 87
4.10 PROFIT MARGIN SCENARIO 89
4.10.1 MARGIN IMPROVEMENT DRIVERS 89
4.10.2 COST PRESSURE 89
4.10.3 REGIONAL VARIATIONS 89
4.10.4 FUTURE SCENARIOS 90
4.11 CLIMATE CHANGE SCENARIO 91
4.11.1 ENVIRONMENTAL CONCERNS 91
4.11.2 INDUSTRY RESPONSE 91
4.11.3 GOVERNMENT'S ROLE 91
4.11.4 ANALYST RECOMMENDATIONS 92
4.12 INNOVATION TRACKER AND STRATEGIC ANALYSIS 93
4.12.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS 93
4.12.1.1 JOINT VENTURES 93
4.12.1.2 MERGERS AND ACQUISITIONS 93
4.12.1.3 LICENSING AND PARTNERSHIP 93
4.12.1.4 TECHNOLOGY COLLABORATIONS 93
4.12.2 STRATEGIC DIVESTMENTS 94
4.12.3 STAGE OF DEVELOPMENT 94
4.12.4 TIMELINES AND MILESTONES 94
4.12.5 INNOVATION STRATEGIES AND METHODOLOGIES 94
4.12.6 RISK ASSESSMENT AND MITIGATION 94
4.12.7 FUTURE OUTLOOK 95
4.13 PRICING ANALYSIS 96
4.13.1 HEMOSTATIC CLIPS AND FORCEPS PRICING 96
4.13.2 BANDING AND COAGULATION DEVICES 97
4.13.3 REGULATORY AND REIMBURSEMENT IMPACT 97
4.14 SUPPLY CHAIN ANALYSIS 98
4.14.1 OVERVIEW 98
4.14.2 LOGISTIC COST SCENARIO 98
4.14.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS 98
4.14.4 CONCLUSION 99
5 TARIFFS & IMPACT ON THE MARKET 100
5.1 OVERVIEW 100
5.2 CURRENT TARIFF RATE (S) IN TOP-5 COUNTRY MARKETS 100
5.3 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE 100
5.4 VENDOR SELECTION CRITERIA 101
5.5 IMPACT ON SUPPLY CHAIN 101
5.5.1 RAW MATERIAL PROCUREMENT 101
5.5.2 MANUFACTURING AND PRODUCTION 101
5.5.3 LOGISTICS AND DISTRIBUTION 101
5.5.4 PRICE PITCHING AND POSITION OF MARKET 101
5.6 INDUSTRY PARTICIPANTS: PROACTIVE MOVES 101
5.6.1 SUPPLY CHAIN OPTIMIZATION 101
5.6.2 JOINT VENTURE ESTABLISHMENTS 101
5.7 IMPACT ON PRICES 102
5.8 REGULATORY INCLINATION 102
5.8.1 GEOPOLITICAL SITUATION 102
5.8.2 TRADE PARTNERSHIPS BETWEEN THE COUNTRIES 102
5.8.2.1 FREE TRADE AGREEMENTS 102
5.8.2.2 ALLIANCES ESTABLISHMENTS 102
5.8.3 STATUS ACCREDITATION (INCLUDING MFTN) 102
5.8.4 DOMESTIC COURSE OF CORRECTION 102
5.8.4.1 INCENTIVE SCHEMES TO BOOST PRODUCTION OUTPUTS 102
5.8.4.2 ESTABLISHMENT OF SEZS/INDUSTRIAL PARKS 102
6 REGULATION COVERAGE 103
6.1 PRODUCT CODES 103
6.2 CERTIFIED STANDARDS 103
6.3 SAFETY STANDARDS 104
6.3.1 MATERIAL HANDLING & STORAGE 104
6.3.2 TRANSPORT & PRECAUTIONS 104
6.3.3 HAZARD IDENTIFICATION 104
7 MARKET OVERVIEW 105
7.1 DRIVERS 107
7.1.1 RISE IN GASTROINTESTINAL BLEEDING CASES 107
7.1.2 AGING POPULATION DRIVING INCREASED DEMAND FOR GI DISORDERS 108
7.1.3 ADOPTION OF MINIMALLY INVASIVE ENDOSCOPIC PROCEDURES 109
7.1.4 RISING AWARENESS AND EXPANDED SCREENING PROGRAMS FOR GASTROINTESTINAL ENDOSCOPY 110
7.2 RESTRAINTS 111
7.2.1 HIGH COST AND TECHNICAL COMPLEXITY OF ENDOSCOPIC HEMOSTASIS DEVICES 111
7.2.2 LIMITED AWARENESS IN LOW-INCOME COUNTRIES 112
7.3 OPPORTUNITIES 113
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN HEMOSTASIS DEVICES 113
7.3.2 EXPANSION IN EMERGING MARKETS (ASIA-PACIFIC, LATIN AMERICA) 114
7.3.3 GROWING ADOPTION OF HOME-BASED AND CAPSULE ENDOSCOPY SOLUTIONS 115
7.4 CHALLENGES 116
7.4.1 REIMBURSEMENT ISSUES FOR ENDOSCOPIC PROCEDURES 116
7.4.2 COMPLEXITIES IN ENDOSCOPE REPROCESSING AND STERILIZATION PROCESSES 117
8 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE 118
8.1 OVERVIEW 119
8.2 MECHANICAL HEMOSTASIS DEVICES 122
8.2.1 MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 122
8.2.1.1 HEMOSTATIC CLIPS 123
8.2.1.1.1 HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE 123
8.2.1.1.1.1 THROUGH-THE-SCOPE (TTS) CLIPS 123
8.2.1.1.1.2 OVER-THE-SCOPE (OTS) CLIPS 123
8.2.1.1.2 HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL 124
8.2.1.1.2.1 STAINLESS STEEL 124
8.2.1.1.2.2 TITANIUM 124
8.2.1.2 BANDING DEVICES 125
8.2.1.2.1 BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE 125
8.2.1.2.1.1 VARICEAL BANDING KITS 125
8.2.1.2.1.2 OESOPHAGEAL BANDING DEVICES 125
8.2.1.3 HEMOSTATIC FORCEPS 125
8.2.1.4 OTHERS 125
8.2.2 MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 126
8.2.2.1 NORTH AMERICA 126
8.2.2.2 EUROPE 126
8.2.2.3 ASIA-PACIFIC 126
8.2.2.4 SOUTH AMERICA 126
8.2.2.5 MIDDLE EAST & AFRICA 126
8.3 THERMAL DEVICES 127
8.3.1 THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 127
8.3.1.1 ARGON PLASMA COAGULATORS 127
8.3.1.2 HEATER PROBES 127
8.3.1.3 BIPOLAR COAGULATION DEVICES 127
8.3.1.3.1 BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE 128
8.3.1.3.1.1 MONOPOLAR 128
8.3.1.3.1.2 BIPOLAR 128
8.3.1.3.2 BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION 129
8.3.1.3.2.1 UPPER GI BLEEDING 129
8.3.1.3.2.2 LOWER GI BLEEDING 129
8.3.1.4 OTHERS 129
8.3.2 THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 130
8.3.2.1 NORTH AMERICA 130
8.3.2.2 EUROPE 130
8.3.2.3 ASIA-PACIFIC 130
8.3.2.4 SOUTH AMERICA 130
8.3.2.5 MIDDLE EAST & AFRICA 130
8.4 TOPICAL AGENTS AND INJECTABLES 131
8.4.1 TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 131
8.4.1.1 EPINEPHRINE INJECTION 131
8.4.1.2 HEMOSTATIC SPRAY (POWDER) 131
8.4.1.3 HEMOSTATIC GELS 131
8.4.1.4 FIBRIN SEALANTS 132
8.4.1.5 SCLEROSING AGENTS 132
8.4.2 TOPICAL AGENTS AND INJECTABLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 132
8.4.2.1 NORTH AMERICA 132
8.4.2.2 EUROPE 132
8.4.2.3 ASIA-PACIFIC 132
8.4.2.4 SOUTH AMERICA 133
8.4.2.5 MIDDLE EAST & AFRICA 133
8.5 OTHERS 133
8.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 133
8.5.1.1 NORTH AMERICA 133
8.5.1.2 EUROPE 133
8.5.1.3 ASIA-PACIFIC 134
8.5.1.4 SOUTH AMERICA 134
8.5.1.5 MIDDLE EAST & AFRICA 134
9 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE TYPE 135
9.1 OVERVIEW 136
9.2 UPPER GASTROINTESTINAL ENDOSCOPY 138
9.2.1 UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 138
9.2.1.1 BLEEDING ULCER MANAGEMENT 139
9.2.1.2 VARICEAL BLEEDING 139
9.2.1.3 DIEULAFOY LESION 139
9.2.2 UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 139
9.2.2.1 NORTH AMERICA 139
9.2.2.2 EUROPE 139
9.2.2.3 ASIA-PACIFIC 140
9.2.2.4 SOUTH AMERICA 140
9.2.2.5 MIDDLE EAST & AFRICA 140
9.3 LOWER GASTROINTESTINAL ENDOSCOPY 140
9.3.1 LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 140
9.3.1.1 COLONIC BLEEDING 140
9.3.1.2 DIVERTICULAR BLEEDING 141
9.3.2 LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 141
9.3.2.1 NORTH AMERICA 141
9.3.2.2 EUROPE 141
9.3.2.3 ASIA-PACIFIC 141
9.3.2.4 SOUTH AMERICA 141
9.3.2.5 MIDDLE EAST & AFRICA 142
9.4 BRONCHOSCOPIC HEMOSTASIS 142
9.4.1 BRONCHOSCOPIC HEMOSTASIS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 142
9.4.1.1 NORTH AMERICA 142
9.4.1.2 EUROPE 142
9.4.1.3 ASIA-PACIFIC 142
9.4.1.4 SOUTH AMERICA 143
9.4.1.5 MIDDLE EAST & AFRICA 143
9.5 OTHERS 143
9.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 143
9.5.1.1 NORTH AMERICA 143
9.5.1.2 EUROPE 143
9.5.1.3 ASIA-PACIFIC 144
9.5.1.4 SOUTH AMERICA 144
9.5.1.5 MIDDLE EAST & AFRICA 144
10 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION 145
10.1 OVERVIEW 146
10.2 GASTROINTESTINAL BLEEDING 149
10.2.1 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 149
10.2.1.1 PEPTIC ULCER BLEEDING 150
10.2.1.2 ESOPHAGEAL VARICES 150
10.2.1.3 COLORECTAL CANCERS 150
10.2.2 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE 150
10.2.2.1 MECHANICAL HEMOSTASIS DEVICES 150
10.2.2.2 THERMAL DEVICES 151
10.2.2.3 TOPICAL AGENTS AND INJECTABLES 151
10.2.2.4 OTHERS 151
10.2.3 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 151
10.2.3.1 NORTH AMERICA 151
10.2.3.2 EUROPE 151
10.2.3.3 ASIA-PACIFIC 152
10.2.3.4 SOUTH AMERICA 152
10.2.3.5 MIDDLE EAST & AFRICA 152
10.3 NON-GASTROINTESTINAL BLEEDING 152
10.3.1 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 152
10.3.1.1 NASAL BLEEDING (EPISTAXIS) 152
10.3.1.2 POST-SURGICAL BLEEDING 153
10.3.2 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE 153
10.3.2.1 MECHANICAL HEMOSTASIS DEVICES 153
10.3.2.2 THERMAL DEVICES 153
10.3.2.3 TOPICAL AGENTS & INJECTABLES 153
10.3.2.4 OTHERS 154
10.3.3 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND) 154
10.3.3.1 NORTH AMERICA 154
10.3.3.2 EUROPE 154
10.3.3.3 ASIA-PACIFIC 154
10.3.3.4 SOUTH AMERICA 154
10.3.3.5 MIDDLE EAST & AFRICA 155
10.4 TRAUMA MANAGEMENT 155
10.4.1 TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE 155
10.4.1.1 MECHANICAL HEMOSTASIS DEVICES 155
10.4.1.2 THERMAL DEVICES 155
10.4.1.3 TOPICAL AGENTS & INJECTABLES 156
10.4.1.4 OTHERS 156
10.4.2 TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 156
10.4.2.1 NORTH AMERICA 156
10.4.2.2 EUROPE 156
10.4.2.3 ASIA-PACIFIC 156
10.4.2.4 SOUTH AMERICA 157
10.4.2.5 MIDDLE EAST & AFRICA 157
10.5 OTHERS 157
10.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 157
10.5.1.1 NORTH AMERICA 157
10.5.1.2 EUROPE 157
10.5.1.3 ASIA-PACIFIC 158
10.5.1.4 SOUTH AMERICA 158
10.5.1.5 MIDDLE EAST & AFRICA 158
11 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY END USER 159
11.1 OVERVIEW 160
11.2 HOSPITALS 163
11.2.1 HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 163
11.2.1.1 PUBLIC 163
11.2.1.2 PRIVATE 163
11.2.2 HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 164
11.2.2.1 NORTH AMERICA 164
11.2.2.2 EUROPE 164
11.2.2.3 ASIA-PACIFIC 164
11.2.2.4 SOUTH AMERICA 164
11.2.2.5 MIDDLE EAST & AFRICA 164
11.3 AMBULATORY SURGERY CENTERS 165
11.3.1 AMBULATORY SURGERY CENTERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 165
11.3.1.1 NORTH AMERICA 165
11.3.1.2 EUROPE 165
11.3.1.3 ASIA-PACIFIC 165
11.3.1.4 SOUTH AMERICA 165
11.3.1.5 MIDDLE EAST & AFRICA 166
11.4 SPECIALTY CLINICS 166
11.4.1 SPECIALTY CLINICS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 166
11.4.1.1 NORTH AMERICA 166
11.4.1.2 EUROPE 166
11.4.1.3 ASIA-PACIFIC 166
11.4.1.4 SOUTH AMERICA 167
11.4.1.5 MIDDLE EAST & AFRICA 167
11.5 OTHERS 167
11.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 167
11.5.1.1 NORTH AMERICA 167
11.5.1.2 EUROPE 167
11.5.1.3 ASIA-PACIFIC 168
11.5.1.4 SOUTH AMERICA 168
11.5.1.5 MIDDLE EAST & AFRICA 168
12 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL 169
12.1 OVERVIEW 170
12.2 INDIRECT SALES 173
12.2.1 INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE 173
12.2.1.1 OFFLINE 173
12.2.1.2 ONLINE 173
12.2.2 INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 174
12.2.2.1 NORTH AMERICA 174
12.2.2.2 EUROPE 174
12.2.2.3 ASIA-PACIFIC 174
12.2.2.4 SOUTH AMERICA 174
12.2.2.5 MIDDLE EAST & AFRICA 174
12.3 DIRECT SALES 175
12.3.1 DIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 175
12.3.1.1 NORTH AMERICA 175
12.3.1.2 EUROPE 175
12.3.1.3 ASIA-PACIFIC 175
12.3.1.4 SOUTH AMERICA 175
12.3.1.5 MIDDLE EAST & AFRICA 176
13 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 177
13.1 MIDDLE EAST AND AFRICA 179
13.1.1 SAUDI ARABIA 190
13.1.2 UNITED ARAB EMIRATES 209
13.1.3 EGYPT 219
13.1.4 ISRAEL 228
13.1.5 QATAR 238
13.1.6 KUWAIT 247
13.1.7 OMAN 256
13.1.8 BAHRAIN 265
13.1.9 REST OF MIDDLE EAST AND AFRICA 274
14 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: COMPANY LANDSCAPE 283
14.1 COMPANY SHARE ANALYSIS: GLOBAL 283
15 SWOT ANALYSIS 284
16 COMPANY PROFILES MANUFACTURERS 285
16.1 OLYMPUS CORPORATION 285
16.1.1 COMPANY SNAPSHOT 285
16.1.2 REVENUE ANALYSIS 285
16.1.3 COMPANY SHARE ANALYSIS 286
16.1.4 PRODUCT PORTFOLIO 286
16.1.5 RECENT DEVELOPMENT 287
16.2 BOSTON SCIENTIFIC CORPORATION 288
16.2.1 COMPANY SNAPSHOT 288
16.2.2 REVENUE ANALYSIS 288
16.2.3 COMPANY SHARE ANALYSIS 289
16.2.4 PRODUCT PORTFOLIO 289
16.2.5 RECENT DEVELOPMENT 290
16.3 CONMED CORPORATION 291
16.3.1 COMPANY SNAPSHOT 291
16.3.2 REVENUE ANALYSIS 291
16.3.3 COMPANY SHARE ANALYSIS 292
16.3.4 PRODUCT PORTFOLIO 292
16.3.5 RECENT DEVELOPMENT 293
16.4 MEDTRONIC 294
16.4.1 COMPANY SNAPSHOT 294
16.4.2 REVENUE ANALYSIS 294
16.4.3 COMPANY SHARE ANALYSIS 295
16.4.4 PRODUCT PORTFOLIO 295
16.4.5 RECENT DEVELOPMENT 296
16.5 COOK 297
16.5.1 COMPANY SNAPSHOT 297
16.5.2 COMPANY SHARE ANALYSIS 297
16.5.3 PRODUCT PORTFOLIO 298
16.5.4 RECENT DEVELOPMENT 299
16.6 ANKAFERD 300
16.6.1 COMPANY SNAPSHOT 300
16.6.2 PRODUCT PORTFOLIO 300
16.6.3 RECENT DEVEOPMENT 301
16.7 B. BRAUN SE 302
16.7.1 COMPANY SNAPSHOT 302
16.7.2 PRODUCT PORTFOLIO 302
16.7.3 RECENT DEVEOPMENT 302
16.8 CREO MEDICAL GMBH 303
16.8.1 COMPANY SNAPSHOT 303
16.8.2 PRODUCT PORTFOLIO 303
16.8.3 RECENT DEVELOPMENT 303
16.9 DIVERSATEK, INC. 304
16.9.1 COMPANY SNAPSHOT 304
16.9.2 PRODUCT PORTFOLIO 304
16.9.3 RECENT DEVEOPMENT 304
16.10 DUOMED GROUP 305
16.10.1 COMPANY SNAPSHOT 305
16.10.2 PRODUCT PORTFOLIO 305
16.10.3 RECENT DEVEOPMENT 306
16.11 ENDOCLOT PLUS, INC. 307
16.11.1 COMPANY SNAPSHOT 307
16.11.2 PRODUCT PORTFOLIO 307
16.11.3 RECENT DEVEOPMENT 308
16.12 ERBE ELEKTROMEDIZIN GMBH 309
16.12.1 COMPANY SNAPSHOT 309
16.12.2 PRODUCT PORTFOLIO 309
16.12.3 RECENT DEVELOPMENT 310
16.13 FUJIFILM HOLDINGS CORPORATION 311
16.13.1 COMPANY SNAPSHOT 311
16.13.2 REVENUE ANALYSIS 311
16.13.3 PRODUCT PORTFOLIO 312
16.13.4 RECENT DEVELOPMENT 316
16.14 JOHNSON & JOHNSON (ETHICON) 317
16.14.1 COMPANY SNAPSHOT 317
16.14.2 REVENUE ANALYSIS 317
16.14.3 PRODUCT PORTFOLIO 318
16.14.4 RECENT DEVEOPMENT 319
16.15 KARL STORZ SE & CO. KG, TUTTLINGEN 320
16.15.1 COMPANY SNAPSHOT 320
16.15.2 PRODUCT PORTFOLIO 320
16.15.3 RECENT DEVEOPMENT 320
16.16 MEDITALIA S.R.L. 321
16.16.1 COMPANY SNAPSHOT 321
16.16.2 PRODUCT PORTFOLIO 321
16.16.3 RECENT DEVELOPMENT 322
16.17 MICRO-TECH ENDOSCOPY 323
16.17.1 COMPANY SNAPSHOT 323
16.17.2 PRODUCT PORTFOLIO 323
16.17.3 RECENT DEVELOPMENT 324
16.18 MTW ENDOSKOPIE MANUFAKTU 325
16.18.1 COMPANY SNAPSHOT 325
16.18.2 PRODUCT PORTFOLIO 325
16.18.3 RECENT DEVEOPMENT 325
16.19 OVESCO ENDOSCOPY AG 326
16.19.1 COMPANY SNAPSHOT 326
16.19.2 PRODUCT PORTFOLIO 326
16.19.3 RECENT DEVEOPMENT 327
16.20 PENTAX MEDICAL 328
16.20.1 COMPANY SNAPSHOT 328
16.20.2 SOLUTION PORTFOLIO 328
16.20.3 RECENT DEVELOPMENT 328
16.21 STERIS 329
16.21.1 COMPANY SNAPSHOT 329
16.21.2 REVENUE ANALYSIS 329
16.21.3 PRODUCT PORTFOLIO 330
16.21.4 RECENT DEVELOPMENT 333
17 COMPANY PROFILES DISTRIBUTOR 334
17.1 BOSTON IVY HEALTHCARE SOLUTIONS PRIVATE LIMITED 334
17.1.1 COMPANY SNAPSHOT 334
17.1.2 PRODUCT PORTFOLIO 334
17.1.3 RECENT DEVELOPMENT 334
17.2 CARDINAL HEALTH 335
17.2.1 COMPANY SNAPSHOT 335
17.2.2 REVENUE ANALYSIS 335
17.2.3 PRODUCT PORTFOLIO 336
17.2.4 RECENT DEVEOPMENT 336
17.3 HENRY SCHEIN, INC. 337
17.3.1 COMPANY SNAPSHOT 337
17.3.2 REVENUE ANALYSIS 337
17.3.3 PRODUCT PORTFOLIO 338
17.3.4 RECENT DEVEOPMENT 338
17.4 MCKESSON MEDICAL-SURGICAL INC. 339
17.4.1 COMPANY SNAPSHOT 339
17.4.2 PRODUCT PORTFOLIO 339
17.4.3 RECENT DEVEOPMENT 340
17.5 MFI MEDICAL 341
17.5.1 COMPANY SNAPSHOT 341
17.5.2 PRODUCT PORTFOLIO 341
17.5.3 RECENT DEVEOPMENT 341
18 QUESTIONNAIRE 342
19 RELATED REPORTS 345
?